Ray Therapeutics develops optogenetic gene therapies that utilize light-sensitive proteins to restore vision in patients with blinding diseases. By targeting specific retinal cells, these therapies aim to improve visual function in individuals suffering from conditions such as retinitis pigmentosa and age-related macular degeneration.
Funding
$106M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CIFounders
Product
Problem
Inherited retinal diseases and age-related macular degeneration lead to progressive vision loss due to the dysfunction or death of photoreceptor cells. Current treatments offer limited efficacy, particularly in advanced stages where significant photoreceptor damage has already occurred. There is a need for therapies that can restore visual function in patients with severe photoreceptor degeneration, regardless of the underlying genetic cause.
Solution
Ray Therapeutics develops optogenetic gene therapies designed to restore vision by making surviving retinal cells light-sensitive. Their approach involves delivering a gene encoding a light-sensitive protein to specific retinal neurons, such as ganglion cells, using a viral vector. Once expressed, this protein enables the modified neurons to respond to light, effectively bypassing the damaged photoreceptors and transmitting visual signals to the brain. This technology aims to provide a therapeutic option for patients with advanced retinal degeneration, offering the potential to regain functional vision despite the loss of photoreceptor cells.
Target Audience
The primary target audience includes patients with advanced retinitis pigmentosa, age-related macular degeneration, and other inherited retinal diseases who have experienced significant photoreceptor loss and have limited treatment options.
Features
- Optogenetic gene therapy approach to restore light sensitivity to retinal neurons
- Utilizes viral vectors for targeted delivery of light-sensitive protein genes
- Focus on retinal ganglion cells as the primary target for optogenetic modification
- Potential to treat a wide range of retinal diseases, regardless of the specific genetic mutation